NeuroSense Therapeutics L...

0.15
-0.05 (-25.00%)
At close: Mar 03, 2025, 11:53 AM
0.21
40.24%
Pre-market: Mar 03, 2025, 11:54 AM EST

NeuroSense Therapeutics Ltd. Income Statement

Year FY23 FY22 FY21 FY20 FY19
Revenue n/a n/a n/a n/a n/a
Cost of Revenue 97K 89K 3K 3K n/a
Gross Profit -97K -89K -3K -3K n/a
Operating Income -12.05M -13.55M -5.59M -2.89M -1.24M
Interest Income 178K 91K n/a 61K 18K
Pretax Income -11.28M -12.34M -4.04M -2.83M -1.22M
Net Income -10.11M -11.2M -2.5M -2.83M -1.23M
Selling & General & Admin 4.78M 7.14M 2.5M 393K 337K
Research & Development 7.27M 6.42M 3.08M 2.5M 898K
Other Expenses n/a n/a n/a n/a n/a
Operating Expenses 10.29M 13.55M 5.59M 2.89M 1.24M
Interest Expense 550K 15K 1.15M 1K 5K
Selling & Marketing Expenses n/a n/a n/a n/a n/a
Cost & Expenses 10.29M 13.55M 5.59M 2.89M 1.24M
Income Tax n/a -1.14M -1.55M 1K 5K
Shares Outstanding (Basic) 13.64M 11.5M 1.94M 1.94M 1.94M
Shares Outstanding (Diluted) 13.64M 11.5M 1.94M 1.94M 1.94M
EPS (Basic) -0.83 -0.97 -1.29 -1.46 -0.63
EPS (Diluted) -0.83 -0.97 -1.29 -1.46 -0.63
EBITDA -10.63M -13.38M -2.88M -2.83M -1.25M
Depreciation & Amortization 97K 89K 3K 3K 1.24M